Oculis Holding announced the appointment of Dr. Snehal Shah, executive leader with over two decades of research & development and regulatory experience, to the role of President of R&D. In this new role, Dr. Shah will be responsible for leading research and development strategies, and working towards achieving market authorizations by directing global regulatory activities required for future New Drug Application submissions to the U.S. FDA, and the equivalent for regulators in other territories.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
- Oculis announces ‘positive’ results from Phase 3 OPTIMIZE-1 trial of OCS-01
- Oculis to Participate at Upcoming April Investor Conferences
- Oculis files $300M mixed securities shelf
- Oculis Holding (NASDAQ:OCS): Riding on Bullish Expectations